Skip to content
Life Sciences Series B Founded 2015

Ulisse BioMed

Ulisse BioMed is a manufacturer of biological drug monitoring and molecular diagnostics. Its Sagitta platform offers molecular diagnostic test kits for the diagnosis and detection of respiratory infections, HPV, and nucleic acid extraction. The company also provides a drug monitoring platform with NanoHybrid technology to detect specific antibodies and protein analytes directly from serum or whole blood. Ulisse…

📍 Udine, Italy · Genomics,

Funding snapshot

Last roundSeries B
Amount$12M
Date11 September 2025
Total raised$18M
Team size39

About

Ulisse BioMed is a manufacturer of biological drug monitoring and molecular diagnostics. Its Sagitta platform offers molecular diagnostic test kits for the diagnosis and detection of respiratory infections, HPV, and nucleic acid extraction. The company also provides a drug monitoring platform with NanoHybrid technology to detect specific antibodies and protein analytes directly from serum or whole blood. Ulisse BioMed is developing a full range of products to monitor patients prescribed with biologics or biosimilars, supporting personalized medicine through therapeutic drug monitoring. Founded in 2015 and headquartered in Udine, Italy, Ulisse BioMed has raised approximately 17.6 million at the Series B stage with investors including Europa and Global Corporate Finance.

Business model

Infectious Diseases > In Vitro Diagnostic Tests > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Theranostics

Institutional investors

Europa Global Corporate Finance

Latest coverage

No articles yet.

Raising like Ulisse BioMed?

Analyze your pitch deck before your next raise.

Analyze My Deck →